Valine

Valine

SCHEMBL786889

CC(C)[C@H](N)C(=O)O.CCCCCC(=O)CCCCC

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.58
KMT2A Q03164 2/20 0.53
MAPT P10636 1/20 0.53
AKR1B1 P15121 1/20 0.45
HAO1 Q9UJM8 1/20 0.44
PLA2G2A P14555 1/20 0.44
PLA2G5 P39877 1/20 0.44
GPR84 Q9NQS5 7/20 0.43
PPARG P37231 7/20 0.43
PPARD Q03181 7/20 0.43
PPARA Q07869 7/20 0.43
HDAC11 Q96DB2 5/20 0.43
TSHR P16473 4/20 0.43
PTPN1 P18031 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TLR2 O60603 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
FABP4 P15090 2/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL4045692 0.90 SLC7A5 (0.71) SLC7A5MAPTAKR1B1PLA2G2APLA2G5
Valine SCHEMBL11005807 0.88 SLC7A5 (0.68) SLC7A5KMT2AMAPTGPR84PPARG
Dodecane SCHEMBL28109673 0.88 SLC7A5 (0.68) SLC7A5KMT2AMAPTGPR84PPARG
Dodecanoate SCHEMBL28278844 0.87 GPR84 (0.63) SLC7A5KMT2AMAPTAKR1B1GPR84
Stearic Acid SCHEMBL11777042 0.87 GPR84 (0.63) SLC7A5KMT2AMAPTAKR1B1GPR84
Stearic Acid SCHEMBL11541589 0.85 GPR84 (0.61) SLC7A5KMT2AMAPTAKR1B1GPR84
Valine SCHEMBL28555130 0.82 SLC7A5 (0.60) SLC7A5KMT2ATSHRALDH1A1MEN1
SCHEMBL15650629 0.82 KMT2A (0.52) KMT2AMAPTHAO1GPR84PPARG
SCHEMBL15649084 0.82 KMT2A (0.52) KMT2AMAPTHAO1GPR84PPARG
Decanoic Acid SCHEMBL31119074 0.82 CA1 (0.52) SLC7A5PLA2G2APLA2G5GPR84FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488530-A1 SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS Merck Canada Inc. (CA) 2012-08-22 EP disclosed
US-20120202837-A1 SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS MERCK CANADA INC. (CA) 2012-08-09 US disclosed
US-20120071506-A1 METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES GALLEY GUIDO (DE) 2012-03-22 US disclosed
WO-2011057382-A1 SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2011-05-19 WO disclosed
EP-1981499-A1 USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 EP disclosed
US-20070197620-A1 Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles HOFFMANN-LA ROCHE INC. 2007-08-23 US disclosed
WO-2007085558-A1 USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071506-A1 METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES CRY1, PER2, GPR119 SLC7A5 2173/4885KMT2A 1403/4885MAPT 31/4885
US-20120202837-A1 SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS REN, AGTR1, AGTR2 SLC7A5 709/4885KMT2A 4013/4885MAPT 4720/4885
US-20070197620-A1 Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles CRY1, PER2, GPR119 SLC7A5 2353/4885KMT2A 1385/4885MAPT 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.